Hugh M. O'Brodovich, M.D., Joins AIT's Scientific Advisory Board
REHOVOT, Israel, September 17, 2013 /PRNewswire/ --
Israeli biomed company AIT (Advanced Inhalation Therapies Ltd.), a leader in the development of nitric oxide therapeutics for the treatment of infectious respiratory diseases, announced today the appointment of Hugh M. O'Brodovich, M.D.,to its scientific advisory board.
Dr. O'Brodovich holds the position of Arline & Pete Harman Professor & Chair at the Department of Pediatrics Stanford School of Medicine. Dr. O'Brodovich also hold the acts as Pediatric Pulmonologist at the Division of Pulmonary Medicine, Adalyn Jay Physician-in-Chief at Lucile Packard Children's Hospital and Director of Child Health Research Institute at Stanford University.
"I am very pleased to welcome Dr. Hugh M. O'Brodovich to AIT's SAB. His tremendous expertise and research in the field of respiratory distress and pulmonology will greatly contribute to AIT in its successfull studies," says David Greenberg M.D., Chief Medical Officer at AIT and a Professor of Pediatrics and Infectious Diseases at the Soroka Medical Center in Beer Sheva, Israel.
"I am honored to join AIT's scientific advisory board," said Dr. O'Brodovich. "I believe the Company has a very bright future, given its promising therapeutic product pipeline and drug development expertise. I am looking forward to working alongside AIT's experienced management team as they continue to advance the Company's pipeline and forge new strategic collaborations within the industry."
AIT focuses on the development of unique nitric oxide formulations for the treatment of respiratory infectious diseases, including bronchiolitis, cystic fibrosis, pneumonia and asthma. The company is currently conducting Phase II trials for bronchiolitis in infants. Mid-study results demonstrated the safety of AIT's nitric oxide formulation in children.
AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the development and commercialization of formulations from nitric oxide for the treatment of infectious diseases. The company was founded in 2011 by Mor Research Applications, a subsidiary of Clalit Health Services, Israel's largest health management organization.
The company is conducting Phase II trials on bronchiolitis after successful completion of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia, cystic fibrosis and asthma.
Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
SOURCE AIT (Advanced Inhalation Therapies Ltd.)